Mining the code of life for new antibiotics.

Clinical Snapshot

Key Findings

• P Value: Not applicable — no statistical testing performed

• Effect Size: Not applicable — no quantitative effect sizes reported; this is a narrative review

• Primary Outcome: Narrative synthesis of the transition from classical phenotypic screening to digital discovery approaches for antibiotic identification, including in situ cultivation, co-culture, microfluidics, virtual screening, molecular networking, deep learning, genomic/metagenomic mining, and generative design of antimicrobial peptides and small molecules

• Nnt Or Sensitivity: Not applicable — no NNT, sensitivity, specificity, or hazard ratios reported; the review does not present primary clinical outcome data

• Confidence Interval: Not applicable — no confidence intervals reported

Clinical Application

The discovery platforms described (genomic mining, generative peptide design, deep learning-based virtual screening) are currently research-stage tools. Clinical translation requires extensive preclinical validation, toxicology studies, and Phase I–III trials before any described compound could enter clinical use. Feasibility for near-term clinical application is low; medium-to-long-term pipeline enrichment is the realistic benefit Australia faces significant AMR burden, with the ACSQHC and the National Antimicrobial Resistance Strategy 2020–2025 identifying novel antibiotic development as a priority. The TGA has no currently approved agents derived from the computational discovery platforms described in this review. The PBS does not list any generative-design-derived antibiotics. RACGP and ACSQHC antimicrobial stewardship guidelines emphasise preserving existing agents while awaiting pipeline development — this review is relevant to understanding what that pipeline may deliver. Australian research institutions (e.g., Monash University, WEHI) are active in computational drug discovery and may benefit from the methodological frameworks described. The review's relevance to Australian clinicians is currently indirect and prospective rather than immediately actionable. Primarily relevant to researchers, pharmaceutical developers, and policymakers engaged in antibiotic discovery and AMR strategy. Indirect clinical relevance for infectious disease physicians, clinical microbiologists, and antimicrobial stewardship teams seeking to understand the future antibiotic pipeline

Abstract

Antimicrobial resistance (AMR) is outpacing antibiotic development, creating an urgent need for discovery strategies that are faster, broader, and more systematic. Here, we review the transition from classical "dirt mining" and phenotypic screening toward digital discovery approaches that treat chemical structures and biological sequences as searchable, engineerable substrates for antibiotic innovation. Modern extensions of conventional screening, including in situ cultivation, co-culture, and microfluidics, have broadened access to previously uncultured microbes. Computer-aided approaches spanning virtual screening, molecular networking, and deep learning have enabled identification of unconventional antibacterial scaffolds from ultra-large chemical libraries. Mining genomes, proteomes, and metagenomes has uncovered antimicrobial peptides, encrypted peptides, and biosynthetic gene clusters encoding novel small-molecule antibiotics. Generative AI now enables design of peptides and small molecules under multiobjective constraints, including potency, toxicity, stability, and resistance risk. Together, these advances point toward discovery platforms that improve novelty, hit rates, and long-term durability in the face of AMR.

References

1. 1.Crysler, A., & de la Fuente-Nunez, C. (2026). Mining the code of life for new antibiotics. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2026.06.007